Kymera Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Good morning. I'm Eric Joseph, senior biotech analyst with JPMorgan. Our next presenting company is Kymera Therapeutics, and presenting on behalf of the company is CEO Nello Mainolfi. There will be a Q&A after the presentation. There will be mics going around the room. And for those tuning in via on the webcast online, feel free to submit a question via the digital conference book. So with that Nello.
Thanks, Eric. Thanks, everybody, for joining us today. Thanks for the invite Eric and the opportunity to present the story here. So let's start here. Just to provide a bit of context. So Kymera was founded in 2016 with the goal and mission actually to building a fully integrated biotech using targeted protein degradation to develop a new generation of medicines.
Just for those that are not familiar with the technology, I will spend 10 seconds. So targeted protein degradation is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
